



PHARMACEUTICAL 2022











PHARMACEUTICAL 2022



Janux Therapeutics Inc. Rank 14 of 466



The relative strengths and weaknesses of Janux Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Janux Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 46% points. The greatest weakness of Janux Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 304%, being 226% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	377,019
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,797
Liabilities, Non-Current	700
Other Assets	1,393
Other Compr. Net Income	-270
Other Expenses	0
Other Liabilities	0
Other Net Income	257
Other Revenues	3,637
Property and Equipment	1,412
Research and Development	26,237
Selling, General and Administrative Expense	10,329

Output Variable	Value in 1000 USD
Assets	379,824
Liabilities	13,497
Expenses	36,566
Revenues	3,637
Stockholders Equity	366,327
Net Income	-32,672
Comprehensive Net Income	-32,807
Economic Capital Ratio	304%

